NCT05377255View on ClinicalTrials.gov

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

May 10, 2022

Study Completion Date

May 10, 2022

Conditions
Opioid Overdose
Interventions
COMBINATION_PRODUCT

16 mg naloxone AP003

4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device

COMBINATION_PRODUCT

8 mg naloxone NARCAN Nasal Spray

2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device

Trial Locations (1)

33136

Syneos Health Clinical Research Services, Miami

Sponsors
All Listed Sponsors
lead

Emergent BioSolutions

INDUSTRY